Seattle Genetics (SGEN) Gets a Buy Rating from Barclays
In a report released yesterday, Geoff Meacham from Barclays maintained a Buy rating on Seattle Genetics (SGEN), with a price target of $90. The company’s shares closed yesterday at $74.28.
According to TipRanks.com, Meacham is a 4-star analyst with an average return of 4.8% and a 53.0% success rate. Meacham covers the Healthcare sector, focusing on stocks such as DBV Technologies SA – American, Bausch Health Companies Inc, and Johnson & Johnson.
Seattle Genetics has an analyst consensus of Moderate Buy, with a price target consensus of $81.60.
See today’s analyst top recommended stocks >>
The company has a one-year high of $84.37 and a one-year low of $47.75. Currently, Seattle Genetics has an average volume of 874.2K.
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
Seattle Genetics, Inc. is a biotechnology company, which engages in the development and commercialization of antibody-based therapies for the treatment of cancer. Its product Adcetris is an antibody-drug for the treatment of lymphoma. The firm is also advancing a pipeline of novel therapies for solid tumors and blood-related cancers.